Metastatic colorectal cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 34(2023), 1 vom: 01. Jan., Seite 10-32 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cervantes, A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Clinical Practice Guidelines |
---|
Anmerkungen: |
Date Completed 03.01.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.annonc.2022.10.003 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM348213719 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM348213719 | ||
003 | DE-627 | ||
005 | 20231226035643.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.annonc.2022.10.003 |2 doi | |
028 | 5 | 2 | |a pubmed24n1160.xml |
035 | |a (DE-627)NLM348213719 | ||
035 | |a (NLM)36307056 | ||
035 | |a (PII)S0923-7534(22)04192-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cervantes, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Metastatic colorectal cancer |b ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.01.2023 | ||
500 | |a Date Revised 16.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Practice Guideline | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Clinical Practice Guidelines | |
650 | 4 | |a diagnosis | |
650 | 4 | |a follow-up | |
650 | 4 | |a metastatic colorectal cancer | |
650 | 4 | |a treatment | |
700 | 1 | |a Adam, R |e verfasserin |4 aut | |
700 | 1 | |a Roselló, S |e verfasserin |4 aut | |
700 | 1 | |a Arnold, D |e verfasserin |4 aut | |
700 | 1 | |a Normanno, N |e verfasserin |4 aut | |
700 | 1 | |a Taïeb, J |e verfasserin |4 aut | |
700 | 1 | |a Seligmann, J |e verfasserin |4 aut | |
700 | 1 | |a De Baere, T |e verfasserin |4 aut | |
700 | 1 | |a Osterlund, P |e verfasserin |4 aut | |
700 | 1 | |a Yoshino, T |e verfasserin |4 aut | |
700 | 1 | |a Martinelli, E |e verfasserin |4 aut | |
700 | 0 | |a ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 34(2023), 1 vom: 01. Jan., Seite 10-32 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:10-32 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2022.10.003 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 34 |j 2023 |e 1 |b 01 |c 01 |h 10-32 |